Georgina Cunningham

Guy's And St Thomas' NHS Trust
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.

Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.

Journal: Journal of Crohn's & colitis

Published: September 02, 2025

Challenges in gastroenterology training in Australia.

Challenges in gastroenterology training in Australia.

Journal: The lancet. Gastroenterology & hepatology

Published: August 24, 2022

Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?

Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?

Journal: Internal medicine journal

Published: August 10, 2022

An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.

An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.

Journal: Alimentary pharmacology & therapeutics

Published: March 02, 2021

Physiotherapy-assisted prone or modified prone positioning in ward-based patients with COVID-19: a retrospective cohort study.

Physiotherapy-assisted prone or modified prone positioning in ward-based patients with COVID-19: a retrospective cohort study.

Journal: Physiotherapy

Published: December 08, 2020

Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.

Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study.

Journal: Alimentary pharmacology & therapeutics

Published: March 20, 2020

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Can We Predict the Toxicity and Response to Thiopurines in Inflammatory Bowel Diseases?

Journal: Frontiers in medicine

Published: September 30, 2019

Biologic therapies for Crohn's disease: optimising the old and maximising the new.

Biologic therapies for Crohn's disease: optimising the old and maximising the new.

Journal: F1000Research

Published: July 19, 2019

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.

Effectiveness of vedolizumab dose intensification to achieve inflammatory bowel disease control in cases of suboptimal response.

Journal: Frontline gastroenterology

Published: May 09, 2019

Positioning biologics and new therapies in the management of inflammatory bowel disease.

Positioning biologics and new therapies in the management of inflammatory bowel disease.

Journal: Current opinion in gastroenterology

Published: April 26, 2019

Recent advances in monoclonal antibody therapy in IBD: practical issues.

Recent advances in monoclonal antibody therapy in IBD: practical issues.

Journal: Frontline gastroenterology

Published: October 27, 2018

Golimumab in the treatment of ulcerative colitis.

Golimumab in the treatment of ulcerative colitis.

Journal: Therapeutic advances in gastroenterology

Published: September 22, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026